Literature DB >> 20494032

Impact of noncardiac congenital and genetic abnormalities on outcomes in hypoplastic left heart syndrome.

Angira Patel1, Edward Hickey, Constantine Mavroudis, Jeffrey P Jacobs, Marshall L Jacobs, Carl L Backer, Melanie Gevitz, Constantine D Mavroudis.   

Abstract

BACKGROUND: Hypoplastic left heart syndrome may coexist with noncardiac congenital defects or genetic syndromes. We explored the impact of such lesions on outcomes after staged univentricular palliation.
METHODS: Society of Thoracic Surgeons database 2002 to 2006: Children diagnosed with hypoplastic left heart syndrome who underwent stage 1 Norwood (n = 1,236), stage 2 superior cavopulmonary anastamosis (n = 702) or stage 3 Fontan (n = 553) procedures were studied. In-hospital mortality, postoperative complications, and length of stay were compared at each stage between those with and without noncardiac-genetic defects. Congenital Heart Surgeons' Society database 1994 to 2001: All 703 infants enrolled in the Congenital Heart Surgeons' Society critical left ventricular outflow tract obstruction study who underwent primary stage 1 palliation were reviewed. The impact of noncardiac defects-syndromes on survival was explored using multivariable parametric models with bootstrap bagging.
RESULTS: Society of Thoracic Surgeons database: Stage 1 in-hospital mortality (26% vs 20%, p = 0.04) and mean postoperative length of stay (42 versus 31 days, p < 0.0001) were greater, and postoperative complications significantly more prevalent in infants with noncardiac-genetic defects. Congenital Heart Surgeons' Society database: Noncardiac-genetic defects were present in 55 (8%). Early hazard for death after Norwood was significantly worse in infants with noncardiac defects-syndromes (p = 0.008). Chromosomal defects (n = 14) were highly unfavorable: the early risk of death was doubled (10-year survival 25 +/- 9% vs 54 +/- 2%, p = 0.005). Turner syndrome accounted for the majority of chromosomal defects in this population (11 of 14, 79%). Mode of death was rarely attributable to the noncardiac-genetic defect.
CONCLUSIONS: Survival in hypoplastic left heart syndrome is strongly influenced by the presence of noncardiac abnormalities. Strategies to improve mortality in infants with noncardiac abnormalities should be explored. Presence of chromosomal defects, especially Turner syndrome, should enter decision-management options for parents and physicians. 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20494032     DOI: 10.1016/j.athoracsur.2010.02.004

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  19 in total

1.  Complications after the Norwood operation: an analysis of The Society of Thoracic Surgeons Congenital Heart Surgery Database.

Authors:  Christoph P Hornik; Xia He; Jeffrey P Jacobs; Jennifer S Li; Robert D B Jaquiss; Marshall L Jacobs; Sean M O'Brien; Eric D Peterson; Sara K Pasquali
Journal:  Ann Thorac Surg       Date:  2011-09-19       Impact factor: 4.330

2.  Effects of health disparities on survival after neonatal heart surgery: why should racial, ethnic, gender, and socioeconomic status be included in the risk analysis?

Authors:  Joseph J Sistino; Charles Ellis
Journal:  J Extra Corpor Technol       Date:  2011-12

Review 3.  CHD associated with syndromic diagnoses: peri-operative risk factors and early outcomes.

Authors:  Benjamin J Landis; David S Cooper; Robert B Hinton
Journal:  Cardiol Young       Date:  2015-09-08       Impact factor: 1.093

4.  Genomic Contraindications for Heart Transplantation.

Authors:  Danton S Char; Gabriel Lázaro-Muñoz; Aliessa Barnes; David Magnus; Michael J Deem; John D Lantos
Journal:  Pediatrics       Date:  2017-03-02       Impact factor: 7.124

5.  Predictors of Prolonged Hospital Length of Stay Following Stage II Palliation of Hypoplastic Left Heart Syndrome (and Variants): Analysis of the National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC) Database.

Authors:  Carissa M Baker-Smith; Sara W Goldberg; Geoffrey L Rosenthal
Journal:  Pediatr Cardiol       Date:  2015-06-03       Impact factor: 1.655

6.  Intermediate-term mortality and cardiac transplantation in infants with single-ventricle lesions: risk factors and their interaction with shunt type.

Authors:  James S Tweddell; Lynn A Sleeper; Richard G Ohye; Ismee A Williams; Lynn Mahony; Christian Pizarro; Victoria L Pemberton; Peter C Frommelt; Scott M Bradley; James F Cnota; Jennifer Hirsch; Paul M Kirshbom; Jennifer S Li; Nancy Pike; Michael Puchalski; Chitra Ravishankar; Jeffrey P Jacobs; Peter C Laussen; Brian W McCrindle
Journal:  J Thorac Cardiovasc Surg       Date:  2012-02-15       Impact factor: 5.209

7.  Chromosomal Abnormalities Affect the Surgical Outcome in Infants with Hypoplastic Left Heart Syndrome: A Large Cohort Analysis.

Authors:  Dala Zakaria; Xinyu Tang; Rupal Bhakta; Nahed O ElHassan; Parthak Prodhan
Journal:  Pediatr Cardiol       Date:  2017-09-18       Impact factor: 1.655

8.  Copy Number Variants of Undetermined Significance Are Not Associated with Worse Clinical Outcomes in Hypoplastic Left Heart Syndrome.

Authors:  Andrew L Dailey-Schwartz; Hanna J Tadros; Mahshid Sababi Azamian; Seema R Lalani; Shaine A Morris; Hugh D Allen; Jeffrey J Kim; Andrew P Landstrom
Journal:  J Pediatr       Date:  2018-08-29       Impact factor: 4.406

9.  Opportunities and challenges in linking information across databases in pediatric cardiovascular medicine.

Authors:  Sara K Pasqual; Jennifer S Li; Marshall L Jacobs; Samir S Shah; Jeffrey P Jacobs
Journal:  Prog Pediatr Cardiol       Date:  2012-01

10.  Predictors of prolonged length of intensive care unit stay after stage I palliation: a report from the National Pediatric Cardiology Quality Improvement Collaborative.

Authors:  Carissa M Baker-Smith; Carolyn M Wilhelm; Steven R Neish; Thomas S Klitzner; Robert H Beekman; John D Kugler; Gerard R Martin; Carole Lannon; Kathy J Jenkins; Geoffrey L Rosenthal
Journal:  Pediatr Cardiol       Date:  2013-10-09       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.